title: Retinal vein occlusions.
abstract: Retinal vein occlusion (RVO) is a common cause of vision loss in elderly people. The complex pathogenesis of central RVO (CRVO), hemi-RVO (HRVO) and branch RVO (BRVO) makes it an interdisciplinary task. Treatment of RVO should aim at eliminating the complications and vision-disturbing effects of RVO but also include prophylactic measures in order to avoid recurrence of the disease. Problems are mainly caused by the ischemic form of RVO, leading to neovascularization. Several treatment methods have been investigated over the past decades, including drug therapy and surgical methods. Until recently, sufficient evidence-based studies were only available for the effect of grid and scatter laser therapy on RVO. New studies have shown a positive effect of intravitreal therapy with vascular endothelial growth factor inhibitors (anti-VEGF therapy) on the progression of the disease. Ongoing studies are now focusing on different combination therapies. Larger randomized studies will hopefully lead to a commonly accepted regimen for treatment of CRVO and BRVO in the near future.
authors: Wolf
authors: W
authors: Buehl
authors: Stefan
authors: S
authors: Sacu
authors: Ursula
authors: U
authors: Schmidt-Erfurth
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000150:complications; D006801:Humans; D007511:Ischemia / Q000150:complications / Q000209:etiology; D017075:Laser Coagulation; D009389:Neovascularization, Pathologic / Q000209:etiology; D013508:Ophthalmologic Surgical Procedures; D011322:Primary Prevention / Q000379:methods; D012039:Regional Blood Flow; D012164:Retinal Diseases / Q000150:complications / Q000209:etiology; D012170:Retinal Vein Occlusion / Q000150:complications / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D012171:Retinal Vessels / Q000473:pathology / Q000503:physiopathology; D012307:Risk Factors; D055502:Secondary Prevention; D015912:Thrombolytic Therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014657:Vasculitis / Q000150:complications
chemical_list: D000305:Adrenal Cortex Hormones; D042461:Vascular Endothelial Growth Factor A